stockrow
Friday 6 November 2026
Export ZTEKF’s income statement to Excel — free account
Zentek Ltd.
ZTEKF Healthcare Medical Instruments & Supplies
Zentek Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $120,200.00, down 80.8% from fiscal 2025.
- Revenue
- −95.4%
- EPS
- 0.00%
- Free cash flow
- −254.6%
- Total debt
- +6.53%
Quarter to June 2026, against a year earlier
0.36
0.00
0.00%
Follow ZTEKF
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM Jun ’26 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | 0 | 0 | 1 | 0 | 0 | (18.8%) | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (8.52) | (1,071.51) | (1,010.41) | 22.02 | (1,018.89) | 0.00 | (1,018.9) pt | ||||||
| EBT | (2) | (1) | (2) | (1) | (3) | (31) | (11) | (9) | (7) | (7) | (8) | +14.1% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (11,144.44) | (19,790.20) | (39,258.82) | (1,150.61) | (5,881.86) | 0.00 | (5,881.9) pt | ||||||
| Net income | (2) | (1) | (2) | (1) | (3) | (10) | (11) | (9) | (7) | (7) | (8) | +14.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.04) | (0.02) | (0.03) | (0.02) | (0.04) | (0.34) | (0.11) | (0.09) | (0.07) | (0.07) | (0.07) | +6.4% | ||||||
| Cash flow | (0.02) | (0.01) | (0.01) | (0.01) | (0.02) | (0.07) | (0.10) | (0.06) | (0.04) | (0.03) | (0.03) | +5.7% | ||||||
| Capex | (0.01) | (0.01) | (0.02) | (0.02) | (0.01) | (0.03) | (0.02) | 0.00 | 0.00 | 0.01 | (0.01) | n/m | ||||||
| Free cash flow | (0.03) | (0.02) | (0.03) | (0.03) | (0.03) | (0.10) | (0.11) | (0.06) | (0.05) | (0.02) | (0.04) | (3.4%) | ||||||
| Book value | 0.28 | 0.27 | 0.28 | 0.25 | 0.25 | 0.30 | 0.22 | 0.15 | 0.10 | 0.07 | 0.16 | (14.6%) | ||||||
| Shares, m | 62 | 63 | 67 | 77 | 84 | 92 | 103 | 101 | 103 | 106 | 113 | +6.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 0.00 | 0.00 | 4,297.12 | 182.31 | 467.03 | 345.63 | 989.3 | ||||||
| P/B | — | — | — | — | — | 10.19 | 6.85 | 8.13 | 10.78 | 7.91 | 2.28 | 8.8 | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | (662.34) | 4,233.47 | 182.75 | 471.81 | 258.85 | 845.1 | ||||||
| EV/FCF | — | — | — | — | — | (27.36) | (13.09) | (18.72) | (24.65) | (23.04) | (6.83) | (21.4) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (1) | (1) | (1) | (1) | (1) | (6) | (10) | (6) | (5) | (4) | (4) | +12.2% | |||||
| Capex | (1) | 0 | (1) | (1) | (1) | (3) | (2) | 0 | 0 | 1 | (1) | n/m | ||||||
| Free cash flow | (2) | (1) | (2) | (2) | (2) | (10) | (12) | (6) | (5) | (2) | (5) | +2.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 1 | 0 | 1 | 0 | 1 | 24 | 12 | 3 | 1 | (1) | 10 | n/m | |||||
| Net debt | (1) | 0 | (1) | (1) | (2) | (20) | (7) | (2) | 0 | 0 | (11) | n/m | ||||||
| Shareholders’ equity | 17 | 17 | 19 | 19 | 21 | 28 | 23 | 15 | 11 | 7 | 18 | (9.4%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (12.79) | (7.03) | (10.06) | (5.91) | (13.75) | (115.99) | (39.30) | (41.39) | (48.16) | (58.57) | (42.42) | (45.8) pt | |||||
| ROIC | (8.19) | (4.66) | (6.52) | (4.21) | (10.90) | (78.87) | (43.50) | (43.68) | (39.66) | (66.94) | (68.55) | (58.7) pt | ||||||
| ROE | (12.85) | (7.07) | (10.23) | (6.05) | (14.61) | (127.62) | (43.14) | (45.74) | (56.47) | (79.91) | (53.33) | (67.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 25 | 29 | 24 | 17 | 10 | — | (20.5%) | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.04 | 0.01 | — | +2.1% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Mar 2026 · latest quarter Mar 2026
Zentek Ltd. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KRMD KORU Medical Systems, Inc. | $139.9M | — (loss-making) | — (loss-making) | +18.15% (above 0%: growing) | n/m | +26.17% (above 0%: growing) | 65.14% | 5.21% | Compare |
| STXS Stereotaxis Inc. | $105.2M | — (loss-making) | — (loss-making) | −12.82% (below 0%: shrinking) | n/m | +0.45% (above 0%: growing) | 58.49% | (59.56%) | Compare |
| ZTEKF Zentek Ltd. | $62.3M | — (loss-making) | — | −95.36% (below 0%: shrinking) | n/m | −254.61% (below 0%: shrinking) | 0.00% | 0.00% | |
| POCI Precision Optics Corp. | $54.3M | — (loss-making) | — (loss-making) | +41.95% (above 0%: growing) | n/m | −45.64% (below 0%: shrinking) | 25.34% | (1.21%) | Compare |
| DXR Daxor Corporation | $50.4M | 4.0× | 7.6× | −27.62% (below 0%: shrinking) | n/m | −88.56% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| HBIO Harvard Bioscience, Inc. | $38.5M | — (loss-making) | — (loss-making) | +11.13% (above 0%: growing) | n/m | −123.43% (below 0%: shrinking) | 55.57% | (4.30%) | Compare |
| NEPH Nephros Inc. | $33.6M | 18.0× | 20.2× | +18.01% (above 0%: growing) | +66.67% (above 0%: growing) | −251.52% (below 0%: shrinking) | 58.45% | 8.91% | Compare |
| DAVI Davion Healthcare PLC | $32.8M | — | — | — | — | — | — | — | Compare |
| MLSS Milestone Scientific, Inc. | $27.1M | — (loss-making) | — (loss-making) | +22.27% (above 0%: growing) | n/m | +66.68% (above 0%: growing) | 67.24% | (37.37%) | Compare |
| Median of peers | $44.5M | — | — | +18.01% | — | −45.64% | 58.45% | (1.21%) |